Sarcoma response to targeted therapy dynamically polarizes tumor-associated macrophages

In gastrointestinal stromal tumor (GIST), the most common human sarcoma, tumor-associated macrophages (TAMs) have been found to be abundant and surprisingly M1-like, exhibiting antitumoral activities. However, TAMs switch to M2-like during the course of imatinib therapy, but upon drug resistance TAM...

Descripción completa

Detalles Bibliográficos
Autores principales: Cavnar, Michael J, DeMatteo, Ronald P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2014
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4063150/
https://www.ncbi.nlm.nih.gov/pubmed/25050212
http://dx.doi.org/10.4161/onci.28463
_version_ 1782321756018573312
author Cavnar, Michael J
DeMatteo, Ronald P
author_facet Cavnar, Michael J
DeMatteo, Ronald P
author_sort Cavnar, Michael J
collection PubMed
description In gastrointestinal stromal tumor (GIST), the most common human sarcoma, tumor-associated macrophages (TAMs) have been found to be abundant and surprisingly M1-like, exhibiting antitumoral activities. However, TAMs switch to M2-like during the course of imatinib therapy, but upon drug resistance TAMs revert to M1-like. Therefore, the oncologic efficacy of TAM depletion may depend on tumor type and treatment status.
format Online
Article
Text
id pubmed-4063150
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-40631502015-04-17 Sarcoma response to targeted therapy dynamically polarizes tumor-associated macrophages Cavnar, Michael J DeMatteo, Ronald P Oncoimmunology Author's View In gastrointestinal stromal tumor (GIST), the most common human sarcoma, tumor-associated macrophages (TAMs) have been found to be abundant and surprisingly M1-like, exhibiting antitumoral activities. However, TAMs switch to M2-like during the course of imatinib therapy, but upon drug resistance TAMs revert to M1-like. Therefore, the oncologic efficacy of TAM depletion may depend on tumor type and treatment status. Landes Bioscience 2014-04-17 /pmc/articles/PMC4063150/ /pubmed/25050212 http://dx.doi.org/10.4161/onci.28463 Text en Copyright © 2014 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Cavnar, Michael J
DeMatteo, Ronald P
Sarcoma response to targeted therapy dynamically polarizes tumor-associated macrophages
title Sarcoma response to targeted therapy dynamically polarizes tumor-associated macrophages
title_full Sarcoma response to targeted therapy dynamically polarizes tumor-associated macrophages
title_fullStr Sarcoma response to targeted therapy dynamically polarizes tumor-associated macrophages
title_full_unstemmed Sarcoma response to targeted therapy dynamically polarizes tumor-associated macrophages
title_short Sarcoma response to targeted therapy dynamically polarizes tumor-associated macrophages
title_sort sarcoma response to targeted therapy dynamically polarizes tumor-associated macrophages
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4063150/
https://www.ncbi.nlm.nih.gov/pubmed/25050212
http://dx.doi.org/10.4161/onci.28463
work_keys_str_mv AT cavnarmichaelj sarcomaresponsetotargetedtherapydynamicallypolarizestumorassociatedmacrophages
AT dematteoronaldp sarcomaresponsetotargetedtherapydynamicallypolarizestumorassociatedmacrophages

Ejemplares similares